Neurocrine Biosciences, Inc.
Save
14.64B
Market cap
198.11x
Current P/E
Forward P/E

About

Health care
Sector
Medical - Pharmaceuticals
Industry

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia.

Similar securities

Based on sector and market capitalization

Report issue